A final-stage study has found that exenatide, a GLP-1 drug used to treat Type 2 diabetes, showed no benefit in slowing the progression of Parkinson's disease. The 96-week trial, published in The ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

Parkinson's is a brain condition which is responsible for uncontrolled movements. It causes difficulty in talking, walking, ...

Now, a new study from Renmin Hospital of Wuhan University provides strong evidence that kidney failure may also contribute to the development of Parkinson’s disease by triggering the spread of ...

A Colorado Springs family hopes to win what they believe would be a landmark legal verdict by proving to jurors next month ...

Over time, the disease can also affect memory and lead to dementia. A similar condition called Lewy Body Dementia (LBD), ...

The FDA has approved the first and only subcutaneous apomorphine infusion device, apomorphine hydrochloride injection (Onapgo ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...

AI-powered blood test detects Parkinson's disease years before symptoms appear, revolutionizing early diagnosis and treatment ...

In a large cohort of patients with autoimmune diseases, treatment with biologic disease-modifying antirheumatic drugs was ...

A compound that showed early promise in the treatment of Parkinson's disease in fruit flies has also shown neuroprotective ...

WEDNESDAY, Feb. 5, 2025 (HealthDay News) -- Hopes that GLP-1 drugs such as Ozempic and Wegovy could help slow Parkinson's ...